Point-of-care testing Thrombelastography and platelet transfusion



Similar documents
Embedding Point of Care monitoring (ROTEM) in daily practice

Thromboelastometry in neonates and infants undergoing cardiac surgery

Thromboelastometry- The New Coagulation Measurement. Andrew Bernard, MD Associate Professor of Surgery Trauma Center Medical Director UK Healthcare

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

ORIGINAL PAPERS. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism**

Hemostasis analyzer system

Blood Management Today Incorporating TEG

New Oral Anticoagulants

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, th Annual Great Lakes Cancer Nursing Conference Troy, MI

Transfusion Medicine

To assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE

Plumbing 101:! TXA and EMS! Jay H. Reich, MD FACEP! EMS Medical Director! City of Kansas City, Missouri/Kansas City Fire Department!

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

Damage Control in Abdominal Trauma

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Dabigatran (Pradaxa) Guidelines

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

Aktuelle Literatur aus der Notfallmedizin

- Lessons from SHOT Haemorrhage cases

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Critical Bleeding Reversal Protocol

Clinical Guideline N/A. November 2013

DVT/PE Management with Rivaroxaban (Xarelto)

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

Blood products and pharmaceutical emergencies

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

Heparin-induzierte Thrombozytopenie Wann daran denken? Wie behandlen?

Lupus anticoagulant Pocket card

Platelet Review July Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Lupus anticoagulant aptt & drvvt screening panel W Reflex

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

Abnormal Basic Coagulation Testing Laboratory Testing Algorithms

Practice Guidelines for Perioperative Blood Management

Session Number 405 CERTIFICATION REVIEW: HEMATOLOGY AND IMMUNOLOGY


Suggestions for Optimizing Use of Plasma in the Era of TRALI Risk Reduction

Preoperative Laboratory and Diagnostic Studies

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

New Anticoagulants: What to Use What to Avoid

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Management of severe perioperative bleeding Guidelines from the European Society of Anaesthesiology

Multiplate platelet function analysis - application and interpretation

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

High Risk Emergency Medicine

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015

CME Fibrinogen and Hemostasis: A Primary Hemostatic Target for the Management of Acquired Bleeding

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

INR = (patient PT/mean normal PT) ISI.

Guideline Statement for the Treatment of Disseminated Intravascular Coagulation

INDICATIONS FOR BLOOD PRODUCT TRANSFUSIONS

STANDARD BLOOD PRODUCTS AND SERVICES

1. BLOOD GROUP SYSTEMS. Page 1. Haematology LECTURE 10. BLOOD GROUPS AND TRANSFUSIONS OVERVIEW. 1. Blood Group Systems

The trauma patient presents special conditions

East Kent Prescribing Group

Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003

Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

CONTEMPORARY REVERSAL OF ANTICOAGULATION

Coagulation Disorders In Pregnancy

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013

Impact of new (direct) oral anticoagulants in patient blood management

Role of the Medical Director

Warfarin Reversal with Prothrombin Complex Concentrates and Challenges of the New Oral Anticoagulants.

Coagulation Made Simple. Thomas A. Whitehill, M.D. Section of Vascular Surgery

Cirrhosis and Coagulation A Paradigm of Awareness Robert G. Gish MD

Joint Theater Trauma System Clinical Practice Guideline

Evaluation of the Patient with Suspected Platelet Refractory State

What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille

Transfusion Medicine Fellowship Goals & Objectives

Emerging therapies for Intracerebral Hemorrhage

New Anticoagulants: When and Why Should I Use Them? Disclosures

The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly

Thrombin Formation for Children on Lovenox. Steven Ignell, BA

Anticoagulation Essentials! Parenteral and Oral!

4/24/2015. Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department. Learning Objectives.

MANAGING BLEEDING IN THE

The management of cerebral hemorrhagic complications during anticoagulant therapy

Obstetrics and Maternity

37 2 Blood and the Lymphatic System Slide 1 of 34

Transcription:

Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria

Trauma-induced coagulopathy (TIC) Yearbook of Intensive Care and Emergency Medicine 2007:847 Cut vesicles Tissue trauma + Consumption Tissue trauma + Hyperfibrinolysis Thrombomodulin / Protein C Pre-existing disorders Anticoagulation Antiplatelet drugs Blood loss Fluid resuscitation + Dilution Triad of Malfunction (hypothermia, acidosis, hypocalcaemia)

Limitations of routine coagulation tests aptt, PT, fibrinogen, platelet count no informative test results: aptt factor deficit, hyperfibrinolysis, hypothermia, heparin delayed availability of test results > 30 min no assessment of fibrinolysis, hypercoagulability reflect only plasmatic components (pre-analytical error) no validation for monitoring perioperative bleeding no prediction of bleeding methodological limitations

Goal-directed algorithm management Schöchl. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012; 20: 15 JSTEM 2012

Intraoperative diagnostic tools ROTEM TEM Innovations, Munich TEG Analyzer Haemoscope, USA

Thrombelastometry: Therapeutic approach fibrinogen platelet concentrate maximum clot firmness (MCF in mm) maximum lysis (ML) [%] antifibrinolytics clotting time (CT in sec) PCC, fresh frozen plasma

Normal haemostasis

Side effects of platelet transfusion Incidence 1.5-7%, Sepsis 1 : 25.000 Viral infektion (HBV 1 : 320.000-500.000) bakterielle Kontamination TRALI, incidence 1 : 2000-5000 Refractory transfusions

Bleeding and A10 EX < 45 mm and A10 FIB >> 10 mm A10: 36mm A10: 34mm A10: 16mm A10: 30mm Thrombocytopenia (22 G/l) with bleeding but high fibrinogen transfusion of one platelet concentrate

No bleeding, A10 EX 45 mm and A10 FIB >> 10 mm A10: 44mm A10: 40mm A10: 19mm A10: 42mm Thrombocytopenia (48 G/l) compensated by high fibrinogen no more platelet transfusion required

*ABS = acute bleeding score

Platelet transfusion: effect on increment in platelet count and increase in EXTEM (INTEM) MCF (A5, A10) One therapeutic unit of platelets (either whole blood pooled buffy coat platelets from 4 donors or apheresis platelet from 1 donor) contain about 200-300 x 10 9 platelets Increment in platelet count in hematology patients with severe thrombocytopenia (< 50 x 10 9 /L): 12-18 x 10 9 /L (13 x 10 9 /L in cirrhosis) Increase in EXTEM (INTEM) MCF (A5, A10): 8-10 mm (only 5 mm in cirrhosis) No change in EXTEM (INTEM) CT but decreased CFT (x 0.7-0.8); no change in FIBTEM MCF Increase in impedance aggregometry ADP and TRAP AUC from 3 to 7 U and from 5 to 17 U, respectively References: Flisberg et al. Anesth Analg 2009; Kander et al. Anesth Analg 2014; Tripodi et al. Liver Int 2013

Conclusions In this prognostic study, we identified clinically significant platelet dysfunction after trauma in the presence of an otherwise reassuring platelet count and standard clotting studies, with profound implications for mortality. Multiple electrode impedance aggregometry reliably identifies this dysfunction in injured patients, and admission arachidonic acid and collagen responsiveness are sensitive and specific independent predictors of both early and late mortality.

Conclusions PLTEM A10 (= EXTEM A10 FIBTEM A10) (r = 0.85) shows a better correlation to platelet count than EXTEM A10 (r = 0.74). However, PLTEM A10 does not reflect the compensatory effect of high plasma fibrinogen concentration. Therefore, the combination EXTEM A10 < 45 mm and FIBTEM A10 10 mm (which includes the information provided by PLTEM A10) seem to be superior in providing an adequate cut-off value for platelet transfusion in bleeding trauma patients compared to PLTEM (A10 < 25-35 mm) alone. One therapeutic unit of platelets (either whole blood pooled buffy coat platelets from 4 donors or apheresis platelet from 1 donor) contain about 200-300 x 10 9 platelets The increment in platelet count per transfused platelet concentrate in patients with severe thrombocytopenia is 12-18 x 10 9 /L.

Conclusions The increase in in EXTEM A10 per transfused platelet concentrate in in patients with severe thrombocytopenia is is 8-10 mm. Therefore, one platelet concentrate has to to be be administered for each targeted increase in in EXTEM A10 by by 10 10 mm. In In the absence of of clinical relevant bleeding an an EXTEM A10 45 45 mm should not be be used as as a platelet transfusion trigger. However, Sensitivity of thromboelastometry is not to sensitive the effects to of the antiplatelet effects of drugs? antiplatelet drugs. Platelet function tests (e.g. aggregometry, PFA 100) should be used if Therefore, platelet dysfunction whole blood is suspected impedance due aggregometry to antiplatelet (e.g., drugsrotem or trauma platelet itself. or Multiplate) should be use if platelet dysfunction is suspected due to antiplatelet drugs or trauma itself.

Potential conflicts of interest Travel reimbursement, honoraria for lectures and consulting: CSL Behring Fresenius Kabi Verum Diagnostica

Thank you for your attention! www.perioperativebleeding.org gisela.scharbert@meduniwien.ac.at

ROTEM-Tests 1/3 EXTEM Aktivierung der Gerinnung im TEM durch Gewebsthromboplastin Erfassung der Faktoren: VII,X,V,II,I + Thrombozyten INTEM Aktivierung der Gerinnung im TEM durch Thromboplastin Erfassung der Faktoren: XII,XI,IXVIII,X,V,II,I + Thrombozyten

ROTEM-Tests 2/3 FIBTEM Aktivierung wie EXTEM unter Zusatz von Cytochalasin D. Dieser Test hilft den Anteil des Fibrinogens an der im TEM gemessenen Gerinnung festzustellen. APTEM Aktivierung wie EXTEM unter Zusatz von Aprotinin (Antifibrinolytikum). Im Vergleich zum EXTEM kann nach ca. 5 Minuten eine Aussage zur Hyperfibrinolyse gemacht werden.

ROTEM-Tests 3/3 HEPTEM Aktivierung wie INTEM unter Zusatz von Heparinase. Im Vergleich zum INTEM kann eine heparinbedingte Gerinnungsstörung erfasst werden. NATEM Bestimmung eines nicht aktivierten TEM aus nativem Vollblut oder rekalzifiziertem Zitratblut Lech - 2004

TEG Analyzer Haemoscope, USA

Platelet-Mapping Haemoscope, USA Kaolin-aktivierte MA STANDARD P1-aktivierte MA THROMBIN P3-aktivierte MAADP oder AA

Platelet-Mapping Haemoscope, USA Kaolin-aktivierte MA STANDARD P3-aktivierte MAADP oder AA P1-aktivierte MA THROMBIN